Skip to main content
    T

    Traws Pharma Inc (TRAW)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.26
    +0.01 (+3.59%)

    Market Cap: $3.86M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Traws Pharma Inc (TRAW) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Traws Pharma reported revenue of $2.79M for the fiscal year ended Dec 31, 2025, up 1134.5% from the year before. That year, net income was $9.17M with a net margin of 328.7%. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.55M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $5.55M, a compound annual decline of 7.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.79M+1134.5%100.0%-640.7%328.7%
    Dec 2024$226.00K0.0%94.7%-21835.4%-24192.0%
    Dec 2023$226.00K0.0%100.0%-8981.4%-8384.1%
    Dec 2022$226.00K0.0%100.0%-8684.5%-8391.2%
    Dec 2021$226.00K-2.2%100.0%-7299.1%-7151.8%
    Dec 2020$231.00K-89.4%100.0%-10819.5%-10890.5%
    Dec 2019$2.18M+77.8%100.0%-994.0%-985.0%
    Dec 2018$1.23M+56.0%100.0%-1895.9%-1662.1%
    Dec 2017$787.00K-85.8%100.0%-3270.3%-3061.2%
    Dec 2016$5.55MN/A100.0%-427.4%-354.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.79M$226.00K$226.00K$226.00K$226.00K$231.00K$2.18M$1.23M$787.00K$5.55M
    Cost of revenue$0$12.00K$0$0$0$0$0$0$0$0
    Gross profit$2.79M$214.00K$226.00K$226.00K$226.00K$231.00K$2.18M$1.23M$787.00K$5.55M
    Research and development$12.14M$130.31M$11.43M$11.41M$7.30M$16.90M$15.54M$16.92M$19.12M$20.07M
    Operating income-$17.88M-$49.35M-$20.30M-$19.63M-$16.50M-$24.99M-$21.70M-$23.28M-$25.74M-$23.70M
    Net income$9.17M-$54.67M-$18.95M-$18.96M-$16.16M-$25.16M-$21.50M-$20.41M-$24.09M-$19.67M
    EBITDA$8.75MN/A-$20.28M-$18.95M-$16.16MN/A-$21.48M-$20.48M-$24.02M-$19.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$2.62M$0$2.73M$57.00K$57.00K$57.00K$57.00K$56.00K$56.00K
    Gross profit$0$0$0$2.62M$0$2.73M$57.00K$55.00K$57.00K$57.00K$56.00K$56.00K
    Operating income-$3.60M-$3.17M-$6.95M-$7.37M-$4.05M-$1.25M-$5.20M-$8.54M-$8.54M-$123.35M-$5.21M-$4.46M
    Net income-$3.55M-$3.05M-$7.11M-$7.44M-$3.96M-$915.00K$21.49M-$8.47M-$8.47M-$123.14M-$4.98M-$4.18M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $3.82M were 36.0% of total assets of $10.62M, against total liabilities of $11.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$10.62M$24.96M$22.68M$39.37M$55.48M$19.99M$23.67M$17.92M$4.98M$23.23M
    Current assets$7.98M$24.95M$22.66M$39.35M$55.43M$19.78M$23.47M$17.77M$4.90M$23.07M
    Cash and equivalents$3.82M$21.34M$20.82M$38.76M$55.07M$19.02M$22.73M$16.97M$4.02M$21.45M
    Total liabilities$11.25M$56.59M$12.01M$11.06M$9.36M$13.81M$12.10M$12.54M$15.84M$18.11M
    Shareholder equity-$629.00K-$31.63M$10.67M$28.31M$46.12M$6.17M$0$5.39M-$11.69M$4.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.52M$11.47M$8.16M$10.62M$12.44M$15.62M$19.06M$24.96M$8.94M$18.69M$18.17M$22.68M
    Total liabilities$9.65M$9.78M$13.47M$11.25M$7.90M$7.36M$13.06M$56.59M$10.97M$12.59M$12.16M$12.01M
    Cash and equivalents$2.34M$5.02M$3.13M$3.82M$6.42M$13.08M$15.94M$21.34M$5.41M$16.89M$16.39M$20.82M
    Shareholder equity-$2.13M$1.69M-$5.31M-$629.00K$4.54M$8.26M$6.00M-$31.63M-$2.03M-$105.52M$6.01M$10.67M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$29.79M-$17.93M-$16.29M-$19.49M-$23.07M-$20.83M-$22.70M-$23.82M-$15.81M-$31.24M
    Capital expenditures$3.65M$14.00K$0$0$15.00K$55.00K$0$0$0$0
    Free cash flow-$33.44M-$17.95M-$16.29M-$19.49M-$23.09M-$20.89M-$22.70M-$23.82M-$15.81M-$31.24M
    Investing cash flow-$3.65M-$14.00K$0$0-$15.00K-$55.00K$0$0$0$0
    Financing cash flow$33.98M$0$0$55.56M$19.36M$26.65M$35.66M$6.36M$17.42M$7.46M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.48M-$7.50M-$2.58M-$2.76M-$4.01M-$5.98M-$5.44M-$4.04M-$11.48M-$9.85M-$4.42M-$4.43M
    Capital expendituresN/AN/A$2.58M$0$2.58M$0$0$0$0$0$0$14.00K
    Free cash flowN/AN/A-$5.16M-$2.76M-$6.60M-$5.98M-$5.44M-$4.04M-$11.48M-$9.85M-$4.42M-$4.44M
    Last 12 quarters

    Frequently Asked Questions About TRAW

    What is Traws Pharma's annual revenue?

    Traws Pharma reported revenue of $2.79M for the fiscal year ended Dec 31, 2025.

    How fast is Traws Pharma's revenue growing?

    Revenue was up 1134.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 131.1%.

    Is Traws Pharma profitable?

    Yes. Traws Pharma reported net income of $9.17M for the fiscal year ended Dec 31, 2025, with a net margin of 328.7%.

    How much debt does Traws Pharma have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $3.82M.

    What is TRAW's profit margin?

    For the fiscal year ended Dec 31, 2025, Traws Pharma reported gross margin of 100.0%, operating margin of -640.7% and net margin of 328.7%.